<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03088839</url>
  </required_header>
  <id_info>
    <org_study_id>ADP_01</org_study_id>
    <nct_id>NCT03088839</nct_id>
  </id_info>
  <brief_title>Circulating Biomarker for Amyotrophic Lateral Sclerosis (ALS)</brief_title>
  <official_title>Observational Case-Control Study to Identify Circulating miR-218 as a Possible Non-invasive Biomarker of Amyotrophic Lateral Sclerosis (ALS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neuromed IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neuromed IRCCS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Amyotrophic Lateral Sclerosis (ALS) is a rare disease with a worldwide incidence of 2-3 cases&#xD;
      per 100,000 individuals/year and it is characterized by progressive neurodegeneration of&#xD;
      motor neurons. When motor neurons degenerate the ability of the brain to initiate and control&#xD;
      muscle movement is lost. ALS manifests in two forms: Familiar ALS (FALS) with inherited risk&#xD;
      genotypes, accounts for only 10% of cases and sporadic ALS (SALS) without apparent&#xD;
      heritability accounts for 90% of cases. ALS can occur in both female and male subjects at any&#xD;
      age but is more common in people aged over 40.&#xD;
&#xD;
      Although the molecular mechanism underlying the pathogenesis of ALS is still under&#xD;
      investigation, recent research has revealed that diseases affecting motor neurons may be&#xD;
      associated to alterations of RNA metabolism and biogenesis of small non-coding micro RNAs&#xD;
      (miRNAs). miRNAs are circulating molecules, whose expression profiles are widely described to&#xD;
      have an important potential in monitoring the progression of a disease, to promote the&#xD;
      development of more targeted therapies and/or to determine the effectiveness of treatments.&#xD;
      Altered patterns of specific miRNAs expression have been described in several pathological&#xD;
      conditions. Evidence shows a significant reduction in the levels of certain miRNAs also in&#xD;
      patients with ALS. Among others, miRNA-218 has been described to play a critical role in the&#xD;
      onset of motor neurons differentiation and in establishing cell identity and fate.&#xD;
&#xD;
      Changes in the levels of miRNA-218 in the serum of ALS patients may potentially provide&#xD;
      useful tools to determine the possible association with this disease and to candidate it as&#xD;
      indicator of disease progression.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of circulating miR-218 as biomarker for ALS</measure>
    <time_frame>8 months</time_frame>
    <description>Quantitative assessment of potential changes in the levels of miR-218 in the serum of ALS patients vs healthy controls</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Amyotrophic Lateral Sclerosis (ALS)</condition>
  <arm_group>
    <arm_group_label>30 ALS patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>30 healthy controls</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        A total of 60 individuals (30 subjects clinically diagnosed as ALS patients and 30 healthy&#xD;
        controls) will be recruited at Centre for Rare Diseases, IRCCS Neuromed&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ALS patients admitted to Centre for Rare Diseases, IRCCS Neuromed,&#xD;
&#xD;
          -  Patients diagnosed ALS within 6 months,&#xD;
&#xD;
          -  Patients age between 20 years and 75 years old,&#xD;
&#xD;
          -  Patients underwent to differential diagnosis using diagnostic tools (EMG, NCV, MRI) to&#xD;
             exclude other diseases with similar signs and symptoms,&#xD;
&#xD;
          -  Subjects able to communicate verbally or by using a non-verbal communication system.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women,&#xD;
&#xD;
          -  Subjects with malignant tumor,&#xD;
&#xD;
          -  Subjects/Patients with others neurological or psychiatric disorders,&#xD;
&#xD;
          -  Subjects/Patients with systemic diseases,&#xD;
&#xD;
          -  Subjects/Patients with positive blood test for hepatitis B or C, or HIV,&#xD;
&#xD;
          -  Patients included in other clinical trials,&#xD;
&#xD;
          -  Subjects/Patients showing inability to understand the informed consent and the study's&#xD;
             purpose&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alba Di Pardo</last_name>
    <phone>+39 0865 915212</phone>
    <email>dipardoa@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>IRCCS Neuromed</name>
      <address>
        <city>Pozzilli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alba Di Pardo</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 13, 2017</study_first_submitted>
  <study_first_submitted_qc>March 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2017</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Neuromed IRCCS</investigator_affiliation>
    <investigator_full_name>Alba Di Pardo</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

